Establishes the "Hope for Missouri Patients Act"

HB 2643, the "Hope for Missouri Patients Act," creates a legal framework for patients with life-threatening or severely debilitating conditions to access individualized investigational treatments based on their unique genetic profile. It directly affects eligible patients who have exhausted all FDA-approved treatments, received a physician recommendation for personalized therapy, and provided written informed consent. Key provisions require facilities to comply with federal human subjects protections and define "individualized investigational treatment" as drugs or devices produced exclusively for a patient using their genomic data (excluding those derived from abortion or embryonic stem cells). The bill mandates specific consent documentation detailing treatment alternatives and potential outcomes, without authorizing new drugs or altering FDA approval processes.